Protein-calorie malnutrition is highly prevalent in oncology patients, particularly in the advanced stages of the disease, with an estimated 20–30% of patient deaths attributed to this nutritional state1 1 Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898-913. https://doi.org/10.1016/j.clnu.2021.02.005 https://doi.org/10.1016/j.clnu.2021.02.0... . Loss of lean body mass, muscle strength, and performance, along with increased morbidity and mortality, reduced quality of life, and lower tolerance to treatment toxicity leading to more frequent treatment interruptions, are characteristic features of malnutrition1 1 Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898-913. https://doi.org/10.1016/j.clnu.2021.02.005 https://doi.org/10.1016/j.clnu.2021.02.0... ,2 2 Bossi P, Delrio P, Mascheroni A, Zanetti M. The spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review. Nutrients. 2021;13(6):1980. https://doi.org/10.3390/nu13061980 https://doi.org/10.3390/nu13061980... . Its causes may stem from the cancer itself and/or its treatment and encompass factors such as reduced food intake, increased energy expenditure, metabolic disturbances related to the tumor, and, in some cases, malabsorption. Hyporexia can occur in 40–80% of cases and is multifactorial, potentially arising from issues like nausea, dysgeusia, dysphagia, pain, and depression, among others.